Navigation Links
BioCrossroads' Indiana Seed Fund Invests in Vaccine Biotech Company
Date:2/19/2010

n">June 2005 and is managed by BioCrossroads with funding from BioCrossroads, the Indiana Finance Authority and the Indiana Economic Development Corporation.  The Seed Fund provides working capital in the range of $50,000-$500,000 to promising Indiana life sciences companies at the preliminary stages of operation.

About Bioscience Vaccines

Bioscience Vaccines Inc. (http://www.biosciencevaccines.com) is a company that is developing a biologic material that may aid in the efficacy of vaccines by spurring an immune response.  Their technology is related to Cook Biotech's extracellular matrix technology (ECM), which has been developed into numerous products and used in more than a million patient procedures for the repair of soft tissue. Bioscience Vaccines, Inc., 1400 Cumberland Avenue, West Lafayette, IN 47906

SOURCE BioCrossroads

Back to top

RELATED LINKS

SOURCE BioCrossroads
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. BioCrossroads Launches www.biocrossroadslinx.com and Releases Report on Biopharma Discovery and Development Contract Services
2. Indiana Biopharmaceutical Service Providers Maintain Steady Growth Despite Industry Challenges
3. Indiana Industry, University and Community Leaders Capitalize on Next Generation of States Life Sciences Growth
4. Collaboration of Indianas Health Information Exchanges, State Organizations Submits Application for Health Information Technology Stimulus Funding
5. A New Economic Future for Rural Indiana?: Study to Show How Renewable Energy Could Trigger Boom for Economically Struggling Areas in State
6. Northeast Indiana Regional Partnership to Participate in 2009 Orthopedic Design & Technology Conference & Exhibition
7. Expanding Indianas Breakthroughs in Health Information Technology (Exibhit Indiana): Initiative to Advance the States Health IT National Leadership and Assets Launched to Bring More Awareness to Sector
8. Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation
9. Hoosiers Work for Health Highlights Impact of Medical Research and Innovation on Indiana Economy
10. Lilly Completes Final Phase of Its Indianapolis Biotechnology Complex
11. Medco Chooses AllPoints at Anson in Whitestown, Indiana as Site for the Worlds Largest, Most-Advanced Automated Pharmacy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 2014 Gene synthesis and bioengineering ... entered into a technology access and services agreement ... DNA2.0’s proprietary protein engineering technology, known as “ProteinGPS®” ... are extremely excited that the global leader ADM ... proprietary bioengineering technology has now been validated through ...
(Date:12/17/2014)... CASI Pharmaceuticals, Inc. (Nasdaq: CASI ... and commercialization of innovative therapeutics addressing cancer and other ... primary commercial focus on China , ... C meeting with the U.S. Food and Drug Administration ... February 2015.  During this meeting the Company will seek ...
(Date:12/15/2014)... & PETACH TIKVAH, Israel , Dec. ... BCLI ), a leading developer of adult stem ... subsidiary Brainstorm Cell Therapeutics Ltd. was awarded a grant ... Office of the Chief Scientist (OCS).  This is ... of grant support from the Office of the Chief ...
(Date:12/15/2014)...  Ascendis Pharma A/S, a biotechnology company that ... unmet medical needs, today announced positive six-month interim ... to evaluate once-weekly TransCon Growth Hormone in children ... analysis consists of 25 patients, representing approximately 50% ... completing all six months of treatment. ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4
... Biofuels Key Issues in 2008, NEW YORK, Dec. ... and developments in biofuels are some of the issues,addressed ... The Outlook is produced annually by the Food ... analysis covering all of,the major sectors throughout the food ...
... Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) has completed patient ... investigating the intratumoural,delivery of REOLYSIN(R) in combination ... A total of 23 patients received a ... REOLYSIN(R) at escalating dosages up to a,maximum ...
... Pharmaceuticals,LLC, a clinical stage drug-development company commercializing,first-in-class ... that enhances,oxygen diffusion, today announced that one ... recently recognized as a co-inventor of the ... alpha), a,erythropoiesis stimulating agent (US Patent No. ...
Cached Biology Technology:Rabobank Releases Annual North American Food & Agribusiness Outlook 2Rabobank Releases Annual North American Food & Agribusiness Outlook 3Rabobank Releases Annual North American Food & Agribusiness Outlook 4Oncolytics Biotech Inc. Completes Patient Enrolment in U.K. Phase Ia/Ib Combination REOLYSIN(R)/Radiation Clinical Trial 2Co-Inventor of Amgen's Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals' First-in-Class Oxygen Enhancing Therapeutics 2
(Date:12/17/2014)...  HITLAB SM announced today its completion ... confirm its adherence to current U.S. Food and ... to conduct regulated smart device and smart phone ... safety and research quality. "HITLAB is ... delivery with innovative technology," said Laura Pugliese ...
(Date:12/15/2014)... 2014 Research and Markets ( ... "Global Facial Recognition Market 2015-2019" report ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition is a ... recognition system measures the overall facial feature of ... and the distance between eyes. Facial recognition is ...
(Date:12/11/2014)... , Dec. 10, 2014  Data Sciences International ... has released a new series of digital telemetry ... toxicology researchers. M series, part of the PhysioTel™ ... the best possible physiologic data when incorporating functional ... functional endpoints to toxicology studies has evolved from ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3New telemetry implants expected to change how large animal toxicology studies are conducted 2
... is a metaphorical example of the perfect invasion by a ... a deserted island in the Galapagos Archipelago, the first cancer ... through many generations to establish itself as an invader of ... like any newly stabilized species in different ecological niches, cancer ...
... at Pacific Northwest National Laboratory have developed a ... meet or exceed current and emerging defense and ... Quartz Laser Photo-Acoustic Sensing, or "QPAS," is now ... PNNL, a Department of Energy national laboratory, has ...
... blood pressure measuring above the normal range (less than 120/80 ... strokes, or kidney disease. Lifestyle changes are the first-stage treatment ... , Many patients with high blood ... In so doing, many have consumed danshen, a Chinese herb ...
Cached Biology News:Cancer that colonizes our bodies 2New sensor detects gaseous chemical weapon surrogates in 45 seconds 2Active ingredient in common Chinese herb shown to reduce hypertension 2
Phospho-4E-BP1 (Thr37/46) (236B4) Rabbit mAb Shipping Temperature: Cold Storage Temperature: -20C...
Phospho-TAK1 (Thr184/187) (90C7) Rabbit mAb Shipping Temperature: Cold Storage Temperature: -20C...
... polyclonal to MSY2/YBOX2 ( Abpromise ... Antigen: Synthetic peptide derived ... C-terminus of Human MSY2/YBOX2. (Note: ... (Peptide available as ...
SAPK/JNK Antibody...
Biology Products: